Loading
Instil Bio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Vivo Capital IX, LLC, was filed 25 Mar 2021.
Instil Bio, Inc.: what insiders have been doing
This page follows insider dealings at Instil Bio, Inc. as filed with SEC (Form 4), a company from the Health Care sector. The past year has been quiet: not a single insider filing for Instil Bio, Inc. The previous disclosure was published on 12 September 2025.
Looking back to 2021, when coverage begins, insiders filed 7 purchases and 2 sales.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
32
Thresholds
n/a
Buy Volume
€18M
7 ops. · all time
Sell Volume
€599,540
2 ops. · all time
Who traded when
BuySaleSandeep Laumas2 sales
Since the insiders bought
- -59.2%Entry US$541.20 · Close at T+365 US$220.60
- -59.2%Entry US$541.20 · Close at T+365 US$220.60
- -59.2%Entry US$541.20 · Close at T+365 US$220.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$5.91
Analyst consensus
1 analysts3.00/5
US$7.00Target US$7.00(+18%)US$7.00
Income statement
EBITDA-US$65.8M
Net income-US$71.4M0.0% margin
Valuation
P/Book0.4x
Beta1.94
Balance sheet & cash
Market capUS$40.1M
Total debtUS$85.2M
Free Cash Flow-US$46.6M
Debt / Equity81%
Profitability & ownership
ROE-25.3%
ROA-10.8%
% insiders6.6%
% institutions62.5%
Last declaration on 12 September 2025
Declarations32 total
13,000 shares@ US$12.6815.5% of flowCommon StockSEC:0001789769-25-000087:1
17,539 shares@ US$23.0438.0% of flowCommon StockSEC:0001789769-25-000087:2
12,461 shares@ US$23.8828.0% of flowCommon StockSEC:0001789769-25-000087:3
17,000 shares@ US$11.60100.0% of flowCommon StockSEC:0001789769-25-000087:0
260,323 shares0Common StockSEC:0001567619-22-007150:0
30,000,000 sharesCommon StockSEC:0001209191-21-023011:0
450,000 shares@ US$20.00100.0% of flowCommon StockSEC:0001209191-21-023011:3
Canonical exit: 21 Jun 2021 (T+90)
6,098,799 sharesCommon StockSEC:0001209191-21-023011:1
1,431,274 sharesCommon StockSEC:0001209191-21-023011:2
300,000 shares@ US$20.00100.0% of flowCommon StockSEC:0001209191-21-023066:2
Canonical exit: 21 Jun 2021 (T+90)
104,640 shares@ US$20.0034.9% of flowCommon StockSEC:0001209191-21-023065:5
Canonical exit: 21 Jun 2021 (T+90)
10,470 shares@ US$20.003.5% of flowCommon StockSEC:0001209191-21-023065:6
Canonical exit: 21 Jun 2021 (T+90)
116,880 shares@ US$20.0039.0% of flowCommon StockSEC:0001209191-21-023065:7
Canonical exit: 21 Jun 2021 (T+90)
48,390 shares@ US$20.0016.1% of flowCommon StockSEC:0001209191-21-023065:8
Canonical exit: 21 Jun 2021 (T+90)
19,620 shares@ US$20.006.5% of flowCommon StockSEC:0001209191-21-023065:9
Canonical exit: 21 Jun 2021 (T+90)
450,000 shares@ US$20.00100.0% of flowCommon StockSEC:0001209191-21-023006:3
Canonical exit: 21 Jun 2021 (T+90)
450,000 shares@ US$20.00100.0% of flowCommon StockSEC:0001209191-21-023063:2
Canonical exit: 21 Jun 2021 (T+90)
300,000 shares@ US$20.00100.0% of flowCommon StockSEC:0001209191-21-023064:2
Canonical exit: 21 Jun 2021 (T+90)
477,091 sharesCommon StockSEC:0001209191-21-023066:1
430,431 sharesCommon StockSEC:0001209191-21-023065:2
43,033 sharesCommon StockSEC:0001209191-21-023065:3
480,716 sharesCommon StockSEC:0001209191-21-023065:4
11,709,696 sharesCommon StockSEC:0001209191-21-023064:0
477,091 sharesCommon StockSEC:0001209191-21-023064:1
11,709,696 sharesCommon StockSEC:0001209191-21-023066:0
25 of 32 declarations
About Instil Bio, Inc.
Instil Bio, Inc. is a biopharmaceutical company focused on developing cell therapies for cancer treatment. It utilizes advanced technologies to create innovative and personalized therapies.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
